Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024
Tuesday, October 22, 2024 2 min read
Key Takeaway: Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced a conference call scheduled for October 29, 2024, at 8:30 a.m. Eastern Time. The call will focus on their third quarter 2024 financial results and updates on recent portfolio execution. Interested participants can join via telephone or through a live webcast, with a replay available on their website shortly after the event.
Market Sentiment Analysis
POSITIVE FACTORS
Kiniksa Pharmaceuticals is hosting a conference call to discuss its Q3 2024 financial results.
The company showcases a focus on unmet medical needs with its therapeutic medicines.
Kiniksa's portfolio includes immune-modulating assets with potential differentiation.
Full Press Release Details
LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29, 2024 at 8:30 a.m. Eastern Time to report its third quarter 2024 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.